Research Collaborations: Programs like the ARC Centre of Excellence for Innovations in Peptide and Protein Science are leveraging Australian resources to discover novel peptides and proteins for healthcare applications
A lot of GLP-1 discussion focuses on how much weight is lost
These proteomic data showed that liraglutide exerted a variety of effects on the phosphorylation and expression of proteins in MCAO mice
Overall, the findings suggest potential benefits of GLP-1RA treatment in this high-risk population, although residual confounding and heterogeneity across autoimmune diseases mean the results should not be interpreted as proof of causality
Back Marks, V (1960) 'Response to glucagon by subjects with hyperinsulinism from islet tumours', British Medical Journal , 1, 1539-41
In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02
